the phone call or e-mail that every publication editor dreads. It comes seconds before deadline time, as the content your editorial team has worked for the
last month to produce is committed to print. It comes from a writer whose story has morphed so materially from its original state that it can’t run as
planned—usually leaving a black hole in your layout to be filled at the eleventh hour.
complexity and expense of the small-molecule drug discovery process, from identification and validation of a “drugable” target to the development of an
understanding of the impact of pharmacogenomic differences in patient populations on drug action, lies the “hit-to-lead” process in which compounds that show
activity in an assay system are iteratively improved upon through medicinal chemistry that is guided by more detailed assays and filtering criteria.
Eli Lilly & Co. recently lost an
appeal from a final judgment of the U.S. District Court for the Eastern District of Michigan, finding claims 2, 6, and 7 of U.S. Patent No. 5,464,826 invalid
for obviousness-type double patenting over its earlier U.S. Patent No. 4,808,614. (See, Sun Pharmaceutical Industries v. Lilly, U.S. Court of Appeals for the
Federal Circuit, 2010-1105).